Evidence map›Paper›PMID 35084656›Full record

ReviewCurrent pain and headache reports2022

Gabapentinoid Use in Perioperative Care and Current Controversies.

Akash S Patel, Christopher R Abrecht, Richard D Urman

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04705480 (Pregabalin vs. Gabapentin on Reducing Opioid Usage in Trauma Patients), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04705480 phase4completednot on this map

Pregabalin vs. Gabapentin on Reducing Opioid Usage in Trauma Patients

TypeinterventionalSponsorCAMC Health SystemRan2021 to 2024Enrolled109ConditionsAnalgesics, Gabapentin, Injuries, NarcoticsArmsPregabalin 50mg, Gabapentin 300mg, Neither Pregabalin nor Gabapentin
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Adjuvant Analgesics in Acute Pain - Evaluation of Efficacy.Current pain and headache reports · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Akash S PatelDepartment of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.
Christopher R AbrechtDepartment of Anesthesia & Perioperative Care, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA, 94143, USA.
Richard D UrmanDepartment of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. rurman@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-0516-5977
Brigham and Women's Hospital · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review summarizes the risks and benefits of gabapentinoids (gabapentin and pregabalin) for perioperative pain control and the controversies surrounding their use in a variety of settings. We review current literature with the goal of providing patient-centric and procedure-specific recommendations for the use of these medications. RECENT

findingsGabapentinoids are among the most prescribed medications in the USA, and typically for off-label indications such as postoperative pain. In the perioperative setting, multimodal analgesic or "opioid-sparing" regimens have become the standard of care-and some clinical protocols include gabapentinoids. At the same time, guidelines regarding the perioperative use of gabapentinoids are conflicting and evidence supporting their broad use is lacking. Gabapentinoids administered perioperatively reduce opioid requirements and pain scores for a variety of surgeries. The extent of opioid and pain reduction, however, is not always clinically significant. These medications reduce postoperative nausea and vomiting as well as pruritis, likely as a feature of reducing opioid intake, but are associated with side effects such as dizziness, ataxia, and cognitive dysfunction. Gabapentinoids also increase the risk of respiratory depression, in particular when paired with opioids. There is thus evidence suggesting that the routine use of these medications for perioperative pain management is not recommended. An individualized, patient- and surgery-specific approach should be used, although research is still needed to determine risks and benefits during perioperative use.

Indexed as

AnalgesicsPostoperative PainAnalgesics, OpioidGabapentinHumansPerioperative CarePregabalinAnalgesicsAnalgesics, OpioidGabapentinPregabalinERASGabapentinMultimodalOpioid epidemicPregabalin

Identifiers

PMID35084656
OpenAlexW4210282918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.